Pfizer’s other products, including Eliquis (alliance revenue), Vyndaqel, and Prevnar, will likely see steady sales growth with market share gains. This appears to be a great move for Pfizer, given that it will see a significant drop in sales from its Covid-19 products and some other drugs that lose market exclusivity over the coming years. With higher inflation, the Fed raising interest rates, and concerns over declining earnings in the near term, PFE has fallen 24% in the last twelve months.